ClinConnect ClinConnect Logo
Search / Trial NCT06952153

Comparison of Phaco Surgery With Goniosynechialysis Versus Trabeculectomy in Glaucoma Treatment

Launched by UNIVERSITY OF MEDICINE AND PHARMACY AT HO CHI MINH CITY · Apr 23, 2025

Trial Information

Current as of July 09, 2025

Recruiting

Keywords

Pacg Phaco Gsl Trabeculectomy Rct Ophthalmic Surgery

ClinConnect Summary

This clinical trial is looking at two different surgical methods for treating primary angle-closure glaucoma, a condition that can increase eye pressure and lead to vision loss. The researchers want to find out if a combined procedure called phacoemulsification with goniosynechialysis (Phaco-GSL) is as effective and safe as trabeculectomy, which is a more traditional surgery. They will compare how well each procedure controls eye pressure, any complications that may arise after surgery, and how quickly patients recover their vision.

To participate in the trial, you need to be at least 40 years old and have certain eye conditions, including high eye pressure despite using medications. You will be randomly assigned to one of the two surgical methods and will need to attend follow-up appointments at set times over the next two years to check your eye health and pressure. The trial has not started recruiting participants yet, but if you're interested, it’s a chance to contribute to important research that could help many others with glaucoma.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age ≥ 40 years
  • Peripheral anterior synechiae (PAS) \>180°
  • Glaucomatous optic neuropathy with visual field loss
  • Intraocular pressure (IOP) \> 21 mmHg despite medication
  • Ability to consent and comply with follow-up
  • Cataract grade 1 to 3 according to LOCS III
  • Best corrected visual acuity (BCVA) ≥ 0.3 logMAR (equivalent to 20/40 Snellen or worse)
  • Exclusion Criteria:
  • Very advanced glaucoma (only light perception vision)
  • Secondary angle-closure etiologies
  • Prior ocular surgeries or laser peripheral iridotomy (PI)
  • Allergy to 5-fluorouracil (5-FU), if used postoperatively
  • Irreversible corneal disease
  • Chronic corticosteroid use
  • Poor follow-up compliance
  • Cataract grade 4 or 5 (LOCS III)
  • Phacomorphic, phacolytic, or subluxated cataracts

About University Of Medicine And Pharmacy At Ho Chi Minh City

The University of Medicine and Pharmacy at Ho Chi Minh City is a premier academic institution dedicated to advancing healthcare education and research in Vietnam. Renowned for its commitment to excellence in medical training, the university actively engages in innovative clinical trials aimed at improving patient outcomes and addressing pressing health challenges. By leveraging its extensive network of healthcare professionals and state-of-the-art facilities, the institution fosters collaboration between researchers, clinicians, and industry partners, ensuring the translation of scientific discoveries into effective medical practices. Through its rigorous ethical standards and dedication to patient safety, the university plays a vital role in enhancing the quality of healthcare in the region.

Locations

Ho Chi Minh, , Vietnam

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported